Literature DB >> 31054992

Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations.

Justin Hadar1, Sarah Skidmore1, John Garner1, Haesun Park1, Kinam Park2, Yan Wang3, Bin Qin3, Xiaohui Jiang3.   

Abstract

Poly(lactide-co-glycolide) (PLGA) has been used in many injectable, long-acting depot formulations. Despite frequent use of PLGA, however, its characterization has been limited to measuring its molecular weight, lactide:glycolide (L:G) ratio, and end-group. These conventional methods are not adequate for characterization of unique PLGA polymers, such as branched PLGA. Glucose-initiated PLGA (Glu-PLGA) has been used in Sandostatin® LAR Depot (octreotide acetate for injectable suspension) approved by the U.S. Food and Drug Administration (FDA) in 1998. Glu-PLGA is a branched (also known as star-shaped) polymer and determining its properties has been challenging. It is necessary to develop methods that can determine and characterize the branching parameters of Glu-PLGA. Such characterization is important not only for the quality control of formulations, but also for developing generic parenteral formulations that are required to have the same excipients in the same amount (qualitative/quantitative (Q1/Q2) sameness) as their Reference Listed Drug (RLD). In this study, an analytical technique was developed and validated using a series of branched-PLGA standards, and it was used to determine the branching parameters of Glu-PLGA extracted from Sandostatin LAR, as well as Glu-PLGAs obtained from three different manufacturers. The analytical technique was based on gel-permeation-chromatography with quadruple detection systems (GPC-4D). GPC-4D enabled characterization of Glu-PLGA in its concentration, absolute molecular weight, hydrodynamic radius and intrinsic viscosity. The plot of the branch units per molecule as a function of molar mass provides a unique profile of each branched PLGA. The Mark-Houwink plots were also used to distinguish different Glu-PLGAs. These ensemble identification methods indicate that the branch units of Glu-PLGAs extracted from Sandostatin LAR range from 2 (i.e., linear) at the lower end of the molecular weight to <4 for the majority (94%) of Glu-PLGA.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Branched PLGA; Long-acting depot; Q1/Q2 sameness; Sandostatin; Star-shape PLGA

Mesh:

Substances:

Year:  2019        PMID: 31054992     DOI: 10.1016/j.jconrel.2019.04.039

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

1.  IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin® LAR.

Authors:  Jin-Sook Song; So-Yeon Kim; Jae-Hyun Nam; Jaehwi Lee; Sang-Yong Song; Hasoo Seong
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

Review 2.  Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles.

Authors:  Kinam Park; Andrew Otte; Farrokh Sharifi; John Garner; Sarah Skidmore; Haesun Park; Young Kuk Jhon; Bin Qin; Yan Wang
Journal:  J Control Release       Date:  2020-10-24       Impact factor: 11.467

Review 3.  Poly(Lactic Acid)-Based Microparticles for Drug Delivery Applications: An Overview of Recent Advances.

Authors:  Antonios Vlachopoulos; Georgia Karlioti; Evangelia Balla; Vasileios Daniilidis; Theocharis Kalamas; Myrika Stefanidou; Nikolaos D Bikiaris; Evi Christodoulou; Ioanna Koumentakou; Evangelos Karavas; Dimitrios N Bikiaris
Journal:  Pharmaceutics       Date:  2022-02-04       Impact factor: 6.321

Review 4.  Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review.

Authors:  Yabing Hua; Yuhuai Su; Hui Zhang; Nan Liu; Zengming Wang; Xiang Gao; Jing Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 5.  Challenges and Complications of Poly(lactic-co-glycolic acid)-Based Long-Acting Drug Product Development.

Authors:  Yi Wen Lim; Wen Siang Tan; Kok Lian Ho; Abdul Razak Mariatulqabtiah; Noor Hayaty Abu Kasim; Noorsaadah Abd Rahman; Tin Wui Wong; Chin Fei Chee
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.